Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of human umbilical cord-derived mesenchymal stem cell injection for diabetic foot ulcer
CTR20262118Phase 2Active
- Sponsor
- Saiyi Biotech
- Start
- May 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diabetic foot ulcer (DFU) comparing Human umbilical cord-derived mesenchymal stem cell injection with Placebo (2 arms). Started May 2026; status: active.
02
Drugs
human umbilical cord-derived mesenchymal stem cell injection
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on CTR20262118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262118.